Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report)'s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $8.35 and traded as high as $9.03. Bavarian Nordic shares last traded at $8.92, with a volume of 1,173 shares.
Bavarian Nordic Stock Performance
The business's fifty day simple moving average is $8.40 and its 200 day simple moving average is $8.34. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of 10.98 and a beta of 1.36.
Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported $0.13 EPS for the quarter. The business had revenue of $189.89 million for the quarter. Bavarian Nordic had a return on equity of 11.89% and a net margin of 21.11%. As a group, analysts forecast that Bavarian Nordic will post 0.67 EPS for the current fiscal year.
Bavarian Nordic Company Profile
(
Get Free Report)
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
Further Reading
Before you consider Bavarian Nordic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bavarian Nordic wasn't on the list.
While Bavarian Nordic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.